SPRC

SciSparc Ltd

6.63

Aug 31 • 3:59 PM ET +0.05 (0.76%)

6.50

Aftermarket • 7:40 PM ET -0.13 (-1.96%)

Healthcare Biotechnology Israel Nano NASD

Today, 4:35 PMSciSparc's majority-owned NeuroThera enrolls 26 of planned 60 children in Phase 2 SCI-210 autism spectrum disorder trial

Peers: APRE GOVX KAPA BCDA BIVI KPRX LNAI CALC CVM NEUP

Scroll to Statements

Index	-
Market Cap	3.80M
Enterprise Value	0.47M
Income	-12.18M
Sales	0.86M
Book/sh	104.40
Cash/sh	8.05
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	3
IPO	Aug 30, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	4.42
P/B	0.06
P/C	0.82
P/FCF	-
EV/EBITDA	-
EV/Sales	0.54
Quick Ratio	2.38
Current Ratio	2.41
Debt/Eq	0.09
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-231.49
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	31.81% -13.87%
Sales past 3/5Y	-14.03% -
EPS Y/Y TTM	37.59%
Sales Y/Y TTM	-34.46%
EPS Q/Q	-
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	- -

Insider Own	1.85%
Insider Trans	-4.18%
Inst Own	9.38%
Inst Trans	13.56%
ROA	-135.56%
ROE	-196.55%
ROIC	-287.31%
Gross Margin	46.38%
Oper. Margin	-1022.08%
Profit Margin	-1422.78%
SMA20	-0.93%
SMA50	9.17%
SMA200	-20.10%
Trades

Shs Outstand	0.57M
Shs Float	0.56M
Short Float	3.07%
Short Ratio	0.05
Short Interest	0.02M
52W High	80.10 -91.72%
52W Low	2.98 122.48%
Volatility	5.40% 8.66%
ATR (14)	0.67
RSI (14)	51.12
Beta	2.44
Rel Volume	0.18
Avg Volume	347.22K
Volume	63,068

Perf Week	-0.45%
Perf Month	-6.88%
Perf Quarter	-37.39%
Perf Half Y	47.27%
Perf YTD	-45.83%
Perf Year	-70.05%
Perf 3Y	-99.16%
Perf 5Y	-99.98%
Perf 10Y	-
Recom	-
Target Price	-
Prev Close	6.58
Price	6.63
Change %	0.76%

Today 04:05PM	NeuroThera Labs Achieves Significant Enrollment Momentum in SCI210 Autism Clinical Trial (NewMediaWire)
04:03PM	SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI-210 Autism Clinical Trial (GlobeNewswire)
10:12AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Aug-26-26 08:32AM	SciSparc Advances Agentic AI Strategy with Addition of Internationally Recognized AI Expert Prof. Carmel Domshlak to Scientific Advisory Board (GlobeNewswire)
Aug-24-26 08:51AM	SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation (GlobeNewswire)
08:06AM	Loading…
Aug-18-26 08:06AM	SciSparc: Subsidiary NeuroThera Labs Completes C$5.4 Million Financing with SciSparc's Stake Valued at Approximately C$30 Million (GlobeNewswire)
Aug-12-26 05:01PM	NeuroThera Labs Inc. Closes First Tranche of Non-Brokered Private Placement (NewMediaWire)
09:00AM	NeuroThera Labs Granted Japanese Patent for Its Proprietary, Innovative Therapeutic Combination (NewMediaWire)
08:25AM	SciSparc's Subsidiary NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination (GlobeNewswire)
Aug-05-26 08:48AM	NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-Its-Kind Treatment for Tourette Syndrome (NewMediaWire)
08:22AM	SciSparc: Subsidiary NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette Syndrome (GlobeNewswire)
Jul-31-26 08:20AM	SciSparc: Subsidiary NeuroThera Labs' Quantum Platform Demonstrates Complete End-to-End Hybrid Quantum-Classical Workflow for Clinical Data Analytics (GlobeNewswire) -18.16%
Jul-29-26 10:30AM	SciSparc Advances Quantum Clinical Data Analytics as NeuroThera Validates Proprietary Computing Platform (InvestorsHub) +70.54%
08:32AM	SciSparc: Subsidiary NeuroThera Labs Advances its Quantum Platform for Clinical Data Analytics on a Platform of an S&P 500 company (GlobeNewswire)
Jul-27-26 08:25AM	SciSparc Announces Decision to Target the Agentic AI Market; Forms Scientific Advisory Board for Artificial Intelligence and Cybersecurity (GlobeNewswire) -6.00%
09:27AM	Loading…
Jul-15-26 09:27AM	NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome (NewMediaWire) +14.75%
08:41AM	SciSparc: NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome (GlobeNewswire)
Jun-04-26 07:32AM	SciSparc: Subsidiary NeuroThera Labs Completed Acquisition of CliniQuantum (GlobeNewswire) +21.99%
Jun-03-26 06:04PM	NeuroThera Labs Inc. Announces Closing of Acquisition of Majority Stake in CliniQuantum Ltd. (NewMediaWire) +8.36%
May-28-26 08:40AM	SciSparc: Subsidiary NeuroThera Labs Received Conditional Regulatory Approval for Acquisition of CliniQuantum (GlobeNewswire) +140.32%
Mar-16-26 08:20AM	SciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy (GlobeNewswire)
07:30AM	NeuroThera Labs - Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy (NewMediaWire)
Mar-12-26 07:55AM	SciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease (GlobeNewswire) +22.86%
Mar-11-26 07:30AM	NeuroThera Labs Announces Publication of International Patent in Collaboration With Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease (NewMediaWire)
Mar-10-26 09:28AM	SciSparc: Subsidiary NeuroThera Labs (75%) Signs Definitive Agreement to Acquire Majority Stake in CliniQuantum, Innovator in Quantum-based Clinical trails (GlobeNewswire) -28.34%
07:30AM	Neurothera Labs Inc. Announces Definitive Agreement to Acquire Majority Stake in Cliniquantum Ltd. (NewMediaWire)
Mar-03-26 08:23AM	SciSparc announces 1-for-9 reverse share split (TipRanks)
Mar-02-26 08:00AM	SciSparc Announces 1-for-9 Reverse Share Split (GlobeNewswire) -9.87%
Feb-02-26 08:24AM	SciSparc: NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA (GlobeNewswire)
08:00AM	Neurothera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance Such as MRSA (NewMediaWire)
08:13AM	Loading…
Jan-26-26 08:13AM	SciSparc Successfully Completes Acquisition of IP Portfolio, Advances Toward Immediate Commercialization (GlobeNewswire) -7.92%
Jan-13-26 01:39PM	SciSparc Moves Into Endoscopy With Strategic Patent Deal (Benzinga) -15.52%
06:55AM	SciSparc Signs Definitive Agreement to Acquire a Treasury of Patents for the Endoscope Market- Entering Multi-Billion Dollar Opportunity (GlobeNewswire)
Jan-12-26 04:02PM	SciSparc Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance (GlobeNewswire)
Dec-30-25 08:17AM	SciSparc: Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects (GlobeNewswire)
08:00AM	Neurothera Labs Granted Patent by Israeli Patent Office for Its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects (NewMediaWire)
Dec-02-25 10:25AM	Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company (NewMediaWire)
09:29AM	SciSparc: Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company (GlobeNewswire)
Dec-01-25 08:32AM	SciSparc Plans on Entering the Multi-Billion-Dollar GERD Device Market with Acquisition of an Approved IP Portfolio (GlobeNewswire) -16.36%
Nov-26-25 07:38AM	SciSparc to Acquire Treasury of Patents for Innovative Medical Endoscopy Systems (GlobeNewswire) -9.02%
Nov-20-25 06:42AM	SciSparc: Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression (GlobeNewswire)
Nov-19-25 10:35AM	Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression (NewMediaWire)
Oct-24-25 07:55AM	SciSparc Announces Closing of the Acquisition of a Publicly Traded Company on the TSXV to which it transferred its Advanced Clinical Stage Pharmaceutical Portfolio (GlobeNewswire)
Oct-23-25 04:03PM	SciSparc Announces Closing of the Sale to N2OFF of Majority-Owned Subsidiary MitoCareX, Advancing Drug Discovery for Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer (GlobeNewswire)
08:55AM	SciSparc Targets Quantum-Powered 3D Protein Modeling Technology to Revolutionize AI Drug Discovery (GlobeNewswire)
Oct-20-25 07:41AM	SciSparc-Clearmind Collaboration Leads to Publication of U.S. Patent Application Targeting Binge Behavior Disorders (GlobeNewswire) +12.83%
Oct-15-25 07:05AM	SciSparc Enters into Definitive Agreement for the Acquisition of a Publicly Traded Company on the TSXV to which it will transfer its Advanced Clinical Stage Pharmaceutical Portfolio (GlobeNewswire) +24.35%
Oct-06-25 08:55AM	SciSparc And AutoMax Call Off Merger (Benzinga)
06:40AM	SciSparc Ltd. Announces Framework Agreement Regarding Merger with AutoMax Motors (GlobeNewswire)
Sep-29-25 04:03PM	SciSparc: N2OFF Shareholders Approve Merger with SciSparc's Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer (GlobeNewswire) +35.43%
Sep-25-25 07:05AM	SciSparc Resolves to Launch Innovative Quantum Computing-Enabled 3D Protein Modeling Initiative to Revolutionize AI Drug Discovery (GlobeNewswire) +59.01%
Aug-28-25 09:24AM	SciSparc: AutoMax's Shareholders Approve Merger with SciSparc (GlobeNewswire) -28.87%
06:45AM	SciSparc Shareholders Approve Merger with a Leading Parallel Vehicle Importer in Israel (GlobeNewswire)
Aug-07-25 07:32AM	SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar (GlobeNewswire)
07:32AM	Clearmind Medicine Announces Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar (GlobeNewswire)
Jul-30-25 04:34PM	SciSparc Announces Updates Regarding Proposed Merger; Form F-4 Registration Statement Has Been Declared Effective by SEC (GlobeNewswire) -6.13% -8.92%
08:18AM	Clearmind Medicine Files International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease (GlobeNewswire)
08:12AM	SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease (GlobeNewswire)
Jul-22-25 07:32AM	SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification (GlobeNewswire)
Jun-24-25 05:03PM	SciSparc Announces 1-for-21 Reverse Share Split (GlobeNewswire) +5.80%
May-27-25 07:32AM	SciSparc Announces Publication of Japanese Patent Application (GlobeNewswire)
May-12-25 07:32AM	SciSparc-Clearmind Collaboration Leads to Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction (GlobeNewswire)
07:32AM	Clearmind Medicine Announces Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction (GlobeNewswire)
Apr-25-25 07:59AM	SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders (GlobeNewswire)
Mar-10-25 07:45AM	SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea (GlobeNewswire) +25.16%
07:27AM	Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea (GlobeNewswire)
Mar-03-25 08:25AM	SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers (GlobeNewswire) -11.07%
Feb-27-25 08:45AM	SciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax's Entry into Direct Import of JAC Electric Vehicles (GlobeNewswire)
Feb-26-25 09:29AM	N2OFF Signs Definitive Agreement to Acquire Next-Gen Computational Drug Discovery Company, Targeting Hard To Treat Cancers (GlobeNewswire)
Feb-18-25 07:17AM	SciSparc Secures Favorable Settlement in Lawsuit It Filed, Receiving Cash Compensation and a Full Release from All Commitments, Royalties, and Allegations Asserted Against It on Claimed Core Technology (GlobeNewswire)
Feb-04-25 09:00AM	SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico (GlobeNewswire) -8.89%
Jan-15-25 07:34AM	SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement (GlobeNewswire)
Jan-13-25 08:41AM	SciSparc: AutoMax Enters the Direct Import Market with a $13 Million First Shipment of JAC Electric Vehicles (GlobeNewswire)
Jan-08-25 07:30AM	SciSparc says MitoCareX expands research to pancreatic cancer (TipRanks) -20.92%
Jan-07-25 07:25AM	SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results (GlobeNewswire)
Jan-06-25 11:04AM	Why Is Psychedelic-SciSparc Stock Trading Higher On Monday? (Benzinga) +102.69%
08:15AM	Clearmind Medicine Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment (GlobeNewswire)
07:50AM	SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment (GlobeNewswire)
Jan-02-25 05:14AM	IMCA renews SciSparcs autism spectrum disorder therapy trial approval (Clinical Trials Arena) +9.06%
Dec-31-24 09:24AM	SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder (GlobeNewswire) -22.70%
Dec-27-24 06:50AM	SciSparc: AutoMax announces $13M first delivery of JAC vehicles (TipRanks) -14.20%
Dec-26-24 09:21AM	SciSparc Shares Skyrocket With AutoMax's First JAC Motors Shipment (Benzinga) +126.04%
06:46AM	SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation (GlobeNewswire)
Dec-16-24 07:40AM	SciSparc Provides Updates on Status of Spin-off of its Advanced Clinical Stage Pharmaceutical Portfolio to a Publicly Traded Company (GlobeNewswire) -15.56%
Nov-30-24 06:10AM	Jeffs Brands announces trademark registration approval for Wellution (TipRanks)
Oct-01-24 06:33AM	SciSparc receives FDA approval for trial for Tourette syndrome therapy (Clinical Trials Arena)
Sep-30-24 09:25AM	SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment (GlobeNewswire)
Sep-26-24 09:05AM	SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX (GlobeNewswire)
Sep-23-24 08:17AM	SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment (GlobeNewswire)
Sep-18-24 04:09PM	SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment (GlobeNewswire)
Sep-16-24 04:06PM	SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy (GlobeNewswire) -7.67%
04:06PM	Clearmind Medicine Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy (GlobeNewswire)
Sep-11-24 07:40AM	SciSparc Advances $1.85 million Loan to AutoMax, Following AutoMax's Direct Import Agreement with Major Chinese Vehicle Manufacturer (GlobeNewswire)
Sep-06-24 07:55AM	SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment (GlobeNewswire)
07:55AM	Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment (GlobeNewswire)
Aug-29-24 04:25PM	SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination (GlobeNewswire) -13.04%
04:25PM	Clearmind Medicine Announces Publication of its Patent Application for Innovative Ketamine-Based Combination Treatment (GlobeNewswire)
Aug-28-24 08:55AM	SciSparc Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 Million (GlobeNewswire)
Aug-26-24 04:52AM	SciSparc secures final approval in Israel to start Tourettes Syndrome trial (Clinical Trials Arena) +7.63%
04:32AM	SciSparc seeks FDA IND clearance for Phase IIb Tourette Syndrome treatment trial (Clinical Trials Arena)

SciSparc Ltd. is a clinical stage pharmaceutical company, which focuses on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. It operates through the Drug Development and Online Sales segments. The Drug Development segment focuses on cannabinoid molecules to be approved by an official regulatory authority. The Online Sales segment consists of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States. The company was founded on August 23, 2004 and is headquartered in Tel Aviv, Israel.

President & DirectorMr. Amitai Weiss

Chief Technologies OfficerDr. Adi Zuloff-Shani Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SMITH JAMES EDMOND	10% Owner	Jun 22 '26	Proposed Sale	7.90	73,909	583,881		Jun 22 01:46 PM
Shrem Itschak	Director	Jun 01 '26	Sale	10.00	462	4,620	10,596	Jun 03 08:00 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SPRC

SciSparc Ltd

Upgrade your Finviz experience